DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas.
Diffuse large B-cell lymphomas (DLBCL) are the most common type of aggressive lymphomas, with considerable heterogeneity in clinical presentation, molecular characteristics, and outcome. Previous studies have showed significant correlations between DNA methyltransferase (DNMT) overexpression and unfavorable prognosis in human cancers. Therefore, we investigated in this study the biological and prognostic significance of DNMT1, DNMT3a, and DNMT3b protein expression in DLBCL. DNA methyltransferase (DNMT) expression was analyzed by immunohistochemistry in 81 DLBCL cases and correlated with clinicopathological parameters. Kaplan-Meier curves were used to estimate survival rates, and the Cox proportional hazard regression model was used to evaluate the prognostic impact of DNMT expression. Our results showed that overexpression of DNMT1, DNMT3a, and DNMT3b were detected in 48%, 13%, and 45% of investigated cases, respectively. DNA methyltransferase 1 (DNMT1) and DNMT3b overexpression was significantly correlated with advanced clinical stages (P = 0.028 and P = 0.016, respectively). Moreover, concomitant expression of DNMT1 and DNMT3b was significantly correlated with resistance to treatment (P = 0.015). With regard to survival rates, although data was available only for 40 patients, DNMT3b overexpression was significantly correlated with shorter overall survival (P = 0.006) and progression-free survival (P = 0.016). Interestingly, multivariate analysis demonstrated that DNMT3b overexpression was an independent prognostic factor for predicting shortened overall survival (P = 0.004) and progression-free survival (P = 0.024). In conclusion, DNMT3b overexpression was identified as an independent prognostic factor for predicting shortened survival of patients with DLBCL and could be, therefore, useful in identifying patients who would benefit from aggressive therapy.
Amara
Khaled
K
Department of Pathology, Farhat-Hached Hospital, Sousse, Tunisia.
Ziadi
Sonia
S
Hachana
Mohamed
M
Soltani
Nabil
N
Korbi
Sadok
S
Trimeche
Mounir
M
D000368:Aged; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D000090205:DNA Methyltransferase 3A; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D000097584:DNA Methyltransferase 3B
D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A; D000097584:DNA Methyltransferase 3B; C000717967:DNMT3A protein, human; C000619380:DNMT1 protein, human
Genes Dev. 2007 Dec 1;21(23):3110-22
18056424
J Clin Oncol. 1999 Apr;17(4):1244
10561185
Cancer Res. 2001 May 1;61(9):3581-5
11325823
Nucleic Acids Res. 1997 Nov 15;25(22):4666-73
9358180
Cancer Res. 2001 Apr 15;61(8):3419-24
11309302
Clin Lung Cancer. 2006 Jul;8(1):39-44
16870044
Leukemia. 1998 Mar;12(3):311-6
9529124
Genetics. 1990 Feb;124(2):429-37
2307364
Hum Mol Genet. 2000 Oct;9(16):2395-402
11005794
Int J Cancer. 2007 Dec 15;121(12):2693-702
17724719
Mol Carcinog. 2002 Mar;33(3):163-71
11870882
Nat Rev Genet. 2002 Jun;3(6):415-28
12042769
Hum Pathol. 2003 Jan;34(1):11-7
12605361
Mol Cancer Res. 2004 Jan;2(1):62-72
14757847
Oncol Rep. 2001 Sep-Oct;8(5):1085-9
11496321
Cancer Res. 2003 Oct 1;63(19):6110-5
14559786
Cancer Res. 1999 May 15;59(10):2302-6
10344733
Science. 1980 Nov 7;210(4470):604-10
6254144
Oncogene. 2001 May 28;20(24):3139-55
11420731
Nature. 2000 Feb 3;403(6769):503-11
10676951
Int J Mol Med. 2007 Jul;20(1):65-73
17549390
Mod Pathol. 2008 Mar;21(3):282-96
18165800
Curr Opin Oncol. 2004 Sep;16(5):436-41
15314511
Zhonghua Nei Ke Za Zhi. 2003 Oct;42(10):688-91
14633461
World J Gastroenterol. 2009 Apr 28;15(16):2020-6
19399937
Int J Cancer. 2003 Jul 1;105(4):527-32
12712445
Br J Cancer. 2008 May 20;98(10):1716-22
18414412
Ann Oncol. 2008 Oct;19(10):1774-86
18539616
J Clin Oncol. 2006 Feb 20;24(6):995-1007
16418498
Dig Dis Sci. 2008 Aug;53(8):2083-9
18253830
Lung Cancer. 2007 Feb;55(2):205-13
17140695
Cancer. 2006 Sep 1;107(5):1042-9
16888795
Cell. 1999 Oct 29;99(3):247-57
10555141
Nat Genet. 2003 Jan;33(1):61-5
12496760
Cancer Lett. 2006 Feb 28;233(2):271-8
15885882
Blood. 2001 Mar 1;97(5):1172-9
11222358
Clin Cancer Res. 2003 Oct 1;9(12):4415-22
14555514
Cancer Res. 2006 Sep 1;66(17):8361-6
16951144
Cancer Lett. 2005 Aug 8;226(1):77-84
16004934
Nucleic Acids Res. 1999 Jun 1;27(11):2291-8
10325416
Hum Mol Genet. 2003 Sep 1;12(17):2209-19
12915469
Science. 1997 Sep 26;277(5334):1996-2000
9302295
Blood. 2004 Jan 1;103(1):275-82
14504078
N Engl J Med. 1993 Sep 30;329(14):987-94
8141877